Form 4: Edwards Lifesciences Executive Annette Bruls Reports Stock and Option Grants

Annette Bruls, CVP of EMEACLA at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units.

Summary

• On May 8, 2025, Annette Bruls, CVP of EMEACLA at Edwards Lifesciences Corp, reported changes in beneficial ownership.
• Bruls acquired 6,200 shares of common stock and 31,600 employee stock options.
• These options have an exercise price of $74.63 and expire on May 7, 2032.
• Bruls also acquired 6,200 performance rights.
• The restricted stock units and options vest in four equal annual installments starting one year after the grant date.
• The performance rights vest on May 8, 2028, with the number of shares vesting dependent on performance goals.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating a stable and well-managed company. The sentiment is neutral to positive as it suggests alignment of executive interests with shareholders.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term performance and retention.

Risks

• The value of the stock options is dependent on the future performance of Edwards Lifesciences' stock.
• The vesting of performance rights is contingent on achieving specific performance goals, which may not be met.

Future Outlook

The restricted stock units and options are scheduled to vest and become exercisable commencing one year after the grant date in four equal annual installments. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Industry Context

Equity compensation is a common practice in the medical device industry to incentivize executives and align their interests with those of shareholders. The size and structure of the grants are typical for executives at this level.

Comparison to Industry Standards

• Companies like Medtronic, Abbott, and Boston Scientific also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and performance-based components are generally in line with industry standards for long-term incentive plans.
• The specific number of shares and option grants would be benchmarked against peer companies based on market capitalization and executive level.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value.
• Employees: The grants are part of the company's overall compensation strategy.
• Executives: The grants provide incentives for long-term performance.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, restricted stock units, Edwards Lifesciences, Annette Bruls, performance rights, equity compensation